JP2021529520A5 - - Google Patents

Info

Publication number
JP2021529520A5
JP2021529520A5 JP2020572914A JP2020572914A JP2021529520A5 JP 2021529520 A5 JP2021529520 A5 JP 2021529520A5 JP 2020572914 A JP2020572914 A JP 2020572914A JP 2020572914 A JP2020572914 A JP 2020572914A JP 2021529520 A5 JP2021529520 A5 JP 2021529520A5
Authority
JP
Japan
Prior art keywords
antibody
acid sequence
amino acid
seq
hvr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020572914A
Other languages
English (en)
Japanese (ja)
Other versions
JP7575278B2 (ja
JP2021529520A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/039757 external-priority patent/WO2020006374A2/en
Publication of JP2021529520A publication Critical patent/JP2021529520A/ja
Publication of JP2021529520A5 publication Critical patent/JP2021529520A5/ja
Priority to JP2024071229A priority Critical patent/JP2024119792A/ja
Application granted granted Critical
Publication of JP7575278B2 publication Critical patent/JP7575278B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020572914A 2018-06-29 2019-06-28 抗sirp-ベータ1抗体及びその使用方法 Active JP7575278B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024071229A JP2024119792A (ja) 2018-06-29 2024-04-25 抗sirp-ベータ1抗体及びその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862691913P 2018-06-29 2018-06-29
US62/691,913 2018-06-29
PCT/US2019/039757 WO2020006374A2 (en) 2018-06-29 2019-06-28 Anti-sirp-beta1 antibodies and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024071229A Division JP2024119792A (ja) 2018-06-29 2024-04-25 抗sirp-ベータ1抗体及びその使用方法

Publications (3)

Publication Number Publication Date
JP2021529520A JP2021529520A (ja) 2021-11-04
JP2021529520A5 true JP2021529520A5 (enExample) 2022-07-06
JP7575278B2 JP7575278B2 (ja) 2024-10-29

Family

ID=67439371

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020572914A Active JP7575278B2 (ja) 2018-06-29 2019-06-28 抗sirp-ベータ1抗体及びその使用方法
JP2024071229A Pending JP2024119792A (ja) 2018-06-29 2024-04-25 抗sirp-ベータ1抗体及びその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024071229A Pending JP2024119792A (ja) 2018-06-29 2024-04-25 抗sirp-ベータ1抗体及びその使用方法

Country Status (14)

Country Link
US (2) US12060422B2 (enExample)
EP (1) EP3814377A2 (enExample)
JP (2) JP7575278B2 (enExample)
KR (1) KR20210025614A (enExample)
CN (2) CN119912569A (enExample)
AU (1) AU2019293589A1 (enExample)
BR (1) BR112020026819A2 (enExample)
CA (1) CA3099176A1 (enExample)
EA (1) EA202190138A1 (enExample)
IL (1) IL279648A (enExample)
MA (1) MA53015A (enExample)
MX (1) MX2020013324A (enExample)
SG (1) SG11202010990TA (enExample)
WO (1) WO2020006374A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3317297A4 (en) 2015-06-30 2019-03-20 Sanford-Burnham Medical Research Institute BTLA FUSION PROTEIN AGONISTS AND USES THEREOF
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
BR112022021450A2 (pt) * 2020-04-24 2022-12-27 Millennium Pharm Inc O cd19 ou fragmento de ligação, método de tratamento de um câncer, composição farmacêutica, ácido nucleico, vetor, e, célula isolada
CN116253797B (zh) * 2020-05-19 2024-05-14 益科思特(北京)医药科技发展有限公司 抗新型冠状病毒Spike蛋白抗体及其应用
WO2022115350A1 (en) * 2020-11-30 2022-06-02 Merck Sharp & Dohme Corp. Arginase 1 binders for inhibiting arginase 1 activity
EP4623930A3 (en) * 2020-12-03 2026-02-25 The Board Of Regents Of The University Of Texas System Methods for identifying lilrb-blocking antibodies
CA3231484A1 (en) 2021-10-01 2023-04-06 Qinwen Mao Pathologic tdp-43 as a biomarker for the diagnosis of tdp-43 proteinopathy
CN114478802B (zh) * 2022-01-28 2023-05-26 郑州大学 一种嵌合抗原受体及其应用
EP4619435A1 (en) 2022-11-16 2025-09-24 Boehringer Ingelheim International GmbH Predictive efficacy biomarkers for anti-sirpa antibodies
EP4676953A2 (en) * 2023-03-09 2026-01-14 Triveni Bio, Inc. Dual inhibitor kallikrein antibodies and uses thereof
WO2025049347A1 (en) * 2023-08-25 2025-03-06 Triveni Bio, Inc. Klk5/7 + il-4 targeting antibodies and uses thereof
IL326559A (en) * 2023-08-25 2026-04-01 Triveni Bio Inc Antibodies targeting KLK5/7 + IL-13 and their uses
IL326558A (en) * 2023-08-25 2026-04-01 Triveni Bio Inc KLK5/7 + TH2-targeted antibodies and their uses
WO2025101471A1 (en) * 2023-11-09 2025-05-15 Merck Sharp & Dohme Llc Anti-cd27 antibody cell-based biological potency assay
WO2025166138A1 (en) * 2024-02-02 2025-08-07 Triveni Bio, Inc. Klk5/7 + tslp targeting antibodies and uses thereof
WO2025166146A1 (en) * 2024-02-02 2025-08-07 Triveni Bio, Inc. Klk5/7 + ox40 targeting antibodies and uses thereof

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
ES2052027T5 (es) 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
CA2116774C (en) 1991-09-19 2003-11-11 Paul J. Carter Expression in e. coli antibody fragments having at least a cysteine present as a free thiol. use for the production of bifunctional f(ab') 2 antibodies
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
JP4157160B2 (ja) 1991-12-13 2008-09-24 ゾーマ テクノロジー リミテッド 改変抗体可変領域の調製のための方法
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
WO1993016185A2 (en) 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Biosynthetic binding protein for cancer marker
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
WO1997011971A1 (en) 1995-09-28 1997-04-03 Alexion Pharmaceuticals, Inc. Porcine cell interaction proteins
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
ES2375931T3 (es) 1997-12-05 2012-03-07 The Scripps Research Institute Humanización de anticuerpo murino.
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
PT1222292E (pt) 1999-10-04 2005-11-30 Medicago Inc Metodo para regulacao da transcricao de genes exogenos na presenca de azoto
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
WO2001040307A1 (de) 1999-11-30 2001-06-07 Eberhard-Karls-Universität Tübingen Universitätsklinikum Antikörper gegen signal-regulator-proteine
AU2001247616B2 (en) 2000-04-11 2007-06-14 Genentech, Inc. Multivalent antibodies and uses therefor
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
IL155977A0 (en) 2000-11-30 2003-12-23 Medarex Inc Transgenic transchromosomal rodents for making human antibodies
KR100988949B1 (ko) 2001-10-25 2010-10-20 제넨테크, 인크. 당단백질 조성물
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US20040110704A1 (en) 2002-04-09 2004-06-10 Kyowa Hakko Kogyo Co., Ltd. Cells of which genome is modified
AU2003236017B2 (en) 2002-04-09 2009-03-26 Kyowa Kirin Co., Ltd. Drug containing antibody composition
CA2481837A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
AU2003236020B2 (en) 2002-04-09 2009-03-19 Kyowa Hakko Kirin Co., Ltd. Cell with depression or deletion of the activity of protein participating in GDP-fucose transport
CA2561686C (en) 2004-03-31 2014-12-02 Genentech, Inc. Humanized anti-tgf-beta antibodies
JP4224586B2 (ja) * 2004-04-28 2009-02-18 国立大学法人群馬大学 マクロファージ活性化剤並びにその製造方法及びスクリーニング方法
MY146381A (en) * 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
US7700099B2 (en) 2005-02-14 2010-04-20 Merck & Co., Inc. Non-immunostimulatory antibody and compositions containing the same
ES2965283T3 (es) 2006-03-15 2024-05-28 Alexion Pharma Inc Tratamiento de pacientes con hemoglobinuria paroxística nocturna mediante un inhibidor del complemento
CA2651567A1 (en) 2006-05-09 2007-11-22 Genentech, Inc. Binding polypeptides with optimized scaffolds
DK2059533T3 (da) 2006-08-30 2013-02-25 Genentech Inc Multispecifikke antistoffer
UY30776A1 (es) 2006-12-21 2008-07-03 Medarex Inc Anticuerpos cd44
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
EP3124497B1 (en) 2007-09-14 2020-04-15 Adimab, LLC Rationally designed, synthetic antibody libraries and uses therefor
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
CN101880324B (zh) 2010-05-25 2012-10-17 中国人民解放军第二军医大学 一种抗人SIRPα的单克隆抗体及其细胞株、制备方法和应用
KR102024922B1 (ko) 2010-07-16 2019-09-25 아디맵 엘엘씨 항체 라이브러리
EP3321286B1 (en) 2011-08-23 2021-01-06 Roche Glycart AG Bispecific t cell activating antigen binding molecules
US20140242095A1 (en) 2011-10-19 2014-08-28 University Health Network Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers
AU2013267161A1 (en) * 2012-05-31 2014-11-20 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-L1
WO2014179363A1 (en) 2013-04-29 2014-11-06 Adimab, Llc Polyspecificity reagents, methods for their preparation and use
WO2015138600A2 (en) 2014-03-11 2015-09-17 The Board Of Trustees Of The Leland Stanford Junior University Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies
GB201413357D0 (en) * 2014-07-28 2014-09-10 Philogen Spa Antibodies for treatment and diagnosis
AU2016219772A1 (en) * 2015-02-22 2017-09-21 Sorrento Therapeutics, Inc. Antibody therapeutics that bind CD137
EP3341411B1 (en) 2015-08-28 2025-06-11 Alector LLC Anti-siglec-7 antibodies and methods of use thereof
JP7628764B2 (ja) * 2015-09-29 2025-02-12 アムジエン・インコーポレーテツド Asgr阻害剤
WO2018210795A1 (en) * 2017-05-16 2018-11-22 Synthon Biopharmaceuticals B.V. ANTI-SIRPα ANTIBODIES

Similar Documents

Publication Publication Date Title
US20230322920A1 (en) Multi-specific antibodies and methods of making and using thereof
CN110799539B (zh) 抗4-1bb抗体及其制备和使用方法
JP7575100B2 (ja) 免疫細胞活性化のための二重特異性抗体
Moore et al. Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma
JP2020532947A5 (enExample)
JP2020533948A5 (enExample)
US11787863B2 (en) Multi-specific antibodies and methods of making and using thereof
JP2018518176A5 (enExample)
JP2018525999A5 (enExample)
JP2020500540A5 (enExample)
JP2018518491A5 (enExample)
CA3043656A1 (en) Combination of t-cell redirecting multifunctional antibodies with immune checkpoint modulators and uses thereof
CN117946278A (zh) 多特异性抗体及其制备和使用方法
US12312409B2 (en) Bispecific CD137-binding antibodies for T-cell activation
TW202200618A (zh) 微型導引和導航控制(miniGNC)類抗體蛋白及其製造和使用方法
Lindhofer et al. Trifunctional Triomab® antibodies for cancer therapy
JP7862028B2 (ja) 免疫細胞活性化のための二重特異性抗体
JP2025087939A (ja) がん治療におけるpd-1シグナル阻害剤との組み合わせによる抗tspan8-抗cd3二重特異性抗体の使用
HK40113078A (zh) 抗cd19抗体及其使用和制备方法
TH2101001911A (th) โมเลกุลที่เชื่อมต่อแอนติเจนชนิดไบสเปซิฟิก ซึ่งประกอบรวมด้วยโคลนสารต้าน fap212
HK40019010A (en) Multi-specific antibodies and methods of making and using thereof
HK40116546A (zh) 免疫调节三特异性t细胞接合器融合蛋白